Business Context and Reporting Period
ImmuCell Corporation (ICCC), a Delaware corporation headquartered in Portland, Maine, filed this Form 8-K on May 14, 2026. The filing serves to announce the issuance of a press release containing unaudited financial results for the quarter ended March 31, 2026.
Key Financial Metrics
The provided filing text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) but are not detailed in the body of this 8-K document.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed in the text of this filing. The document solely references the announcement of the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings except as expressly set forth. No specific guidance, management commentary, risks, or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 14, 2026) for the actual unaudited financial figures for the quarter ended March 31, 2026.
- Verify the discrepancy between the filing date (May 14, 2026) and the press release date listed in the exhibit index (April 14, 2026).
- Confirm the company's current status on the NASDAQ Capital Market under the symbol ICCC.